News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_approved_web.jpg)
FDA approves first treatment for advanced epithelioid sarcoma
- Author:
- Laura Nikolaides
Tazemetostat earns accelerated approval for the treatment of patients aged 16 years and older with metastatic or locally advanced epithelioid...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_approved_web.jpg)
FDA approves pembrolizumab for BCG-unresponsive NMIBC with CIS
- Author:
- Laura Nikolaides
The checkpoint inhibitor is approved for patients who are ineligible for or have elected not to undergo cystectomy.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves antibody-drug conjugate for advanced urothelial cancer
- Author:
- Laura Nikolaides
Enfortumab vedotin-ejfv was granted accelerated approval based on an overall response rate of 44%.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA expands Xtandi approval to mCSPC
- Author:
- Laura Nikolaides
Enzalutamide was previously approved for castration-resistant prostate cancer.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves atezolizumab combo as first line for advanced NSCLC
- Author:
- Laura Nikolaides
The approval for first-line treatment was based on results of IMpower 130, which demonstrated an overall survival benefit with atezolizumab in...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA issues warning for CDK 4/6 inhibitors
- Author:
- Laura Nikolaides
In a review of trials and postmarket safety databases, the FDA found there were reports of serious cases of pneumonitis, including fatalities,...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_approved_web.jpg)
FDA approves darolutamide for nonmetastatic CRPC
- Author:
- Laura Nikolaides
The approval was based on improved metastasis free survival in the randomized ARAMIS trial of 1,509 patients with nonmetastatic, castration-...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon_web.jpg)
FDA approves bevacizumab-bvzr for several cancers
- Author:
- Laura Nikolaides
The bevacizumab biosimilar is now approved for metastatic colorectal cancer, advanced non-squamous non–small cell lung cancer, recurrent...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_approved_web.jpg)
FDA approves pembrolizumab for advanced SCLC
- Author:
- Laura Nikolaides
The approval was based on an overall response rate of 19% in two nonrandomized trials.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_approved_web.jpg)
FDA approves trastuzumab-anns for HER2-positive breast, gastric cancer
- Author:
- Laura Nikolaides
This is the fifth FDA approval of a trastuzumab biosimilar.
News
FDA approves NovoTTF-100L System for advanced mesothelioma
- Author:
- Laura Nikolaides
The System delivers electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division and can be prescribed only by a...
News
FDA approves T-DM1 as adjuvant treatment
- Author:
- Laura Nikolaides
The antibody-drug conjugate is approved for patients with HER2-positive early breast cancer who have residual invasive disease following...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves pembrolizumab for first-line stage III NSCLC
- Author:
- Laura Nikolaides
Approval was based on improved overall survival for patients taking pembrolizumab, compared with those taking the investigators’ choice of...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves palbociclib for men with HR+/HER2- advanced breast cancer
- Author:
- Laura Nikolaides
The FDA advises health care providers to tell male patients with female partners of reproductive potential to use effective contraception during...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves cabozantinib for previously treated HCC
- Author:
- Laura Nikolaides
Approval was based on improvement in overall survival versus placebo in the phase 3 CELESTIAL trial.